MYCN amplification is known to be an important marker for poor prognosis in the SHH subgroup of human medulloblastomas [46–50], and the combination of Shh and Mycn have been shown to cause medulloblastomas in mice [51]. This evidence concerns the gene MYCN and medulloblastoma.